Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201204116 Principal Investigator: Lockhart, A. Craig
Title: An open-label, phase II study of vemurafenib in patients with BRAF V600 mutation-positive cancers
Phase: II Disease Site: Multiple Sites
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this research study is to learn whether a drug called vemurafenib is safe and effective in cancers caused by problems with the BRAF gene. Previous studies have shown that vemurafenib therapy can be beneficial in patients with a special type of metastatic melanoma that is caused by problems with the BRAF gene.
 
More Information:
ClinicalTrials.gov Entry
Internal Protocol Documents (requires Siteman administrative database password)